lacutamab

Lacutamab is a first-in-class humanized monoclonal antibody that targets KIR3DL2 receptor, an inhibitory receptor of the KIR family expressed on malignant T cells in cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides, as well as peripheral T-cell lymphoma (PTCL)[1][5][7]. By binding to KIR3DL2 receptor, lacutamab induces cytotoxicity against tumor cells through mechanisms such as antibody-dependent cell cytotoxicity and phagocytosis[6][7]. It is being developed primarily for relapsed or refractory CTCL and PTCL. Lacutamab has received orphan drug status in both the US and EU for CTCL and has been granted FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome after at least two prior systemic therapies[1][4][5]. The drug was originally discovered by the University of Genoa and is being developed by Innate Pharma[7].

Other names

lacutamab